Trial Profile
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 10 Jun 2021 Results published in the Clinical Therapeutics.
- 08 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.